Attached files
file | filename |
---|---|
8-K - LIVE FILING - Savara Inc | htm_47208.htm |
EX-3.1 - EX-3.1 - Savara Inc | exhibit1.htm |
EX-3.2 - EX-3.2 - Savara Inc | exhibit2.htm |
EX-99.2 - EX-99.2 - Savara Inc | exhibit4.htm |
ADVENTRX ANNOUNCES CORPORATE NAME CHANGE TO
MAST THERAPEUTICS, INC.; TICKER SYMBOL CHANGE TO MSTX
Name and ticker symbol changes effective March 11, 2013
SAN DIEGO February 28, 2013 ADVENTRX Pharmaceuticals, Inc. (NYSE MKT: ANX) today announced that, effective March 11, 2013, its corporate name will be Mast Therapeutics, Inc.
Brian M. Culley, Chief Executive Officer, said: The new corporate identity we announce today is the final step in a transformational process through which we have changed fundamentally this companys priorities, personnel and business focus. In 2009, substantially all of our business operations were suspended and we had 2 employees. Since then, we have appointed a new management team and Board of Directors, acquired ANX-188, the most clinically advanced new drug in sickle cell disease, initiated a pivotal phase 3 study in this orphan indication, and announced our plans to initiate a phase 2 study of ANX-188 in acute limb ischemia, a complication of peripheral arterial disease. We no longer are developing reformulated chemotherapeutic products. Our company today is dramatically different from 12 months ago and the Adventrx name no longer reflects our strategic vision.
Mr. Culley continued: We now have in place the right team, the right programs and the opportunity to bring new therapies to patients with significant unmet needs in multiple therapeutic areas. This weeks introduction of the MAST platform and our plans to develop ANX-188 for complications of arterial disease solidify our commitment to this franchise. Our new corporate identity embodies the fundamental changes that have taken place over the past several years and reflects that, in a very fundamental sense, we are a new company.
Details Regarding Name Change from ADVENTRX Pharmaceuticals to Mast Therapeutics
The following changes will be effective prior to trading on Monday, March 11, 2013:
| The Companys name will be Mast Therapeutics, Inc.. |
| The Companys common stock will be traded on the NYSE MKT under the ticker symbol MSTX (currently, ANX). |
| A new CUSIP number of 576314 108 will be assigned to the Companys common stock and a new CUSIP number of 576314 116 will be assigned to the common stock purchase warrants of the Company that were issued in November 2011. |
| The Companys website will be available at www.masttherapeutics.com (currently, www.adventrx.com). |
| The Companys lead product candidate will be referred to as MST-188 (currently, ANX-188). |
Outstanding stock certificates and warrants for shares of the Companys common stock are not affected by the name change; they will continue to be valid and need not be exchanged.
About ADVENTRX Pharmaceuticals
ADVENTRX Pharmaceuticals is a publicly traded biopharmaceutical company headquartered in San Diego,
CA. The Company is leveraging the MAST (Molecular Adhesion and Sealant Technology) platform,
derived from over two decades of clinical, nonclinical and manufacturing experience with purified
and non-purified poloxamers, to develop ANX-188, its lead product candidate, for serious or
life-threatening diseases with significant unmet needs. ANX-188 is a cytoprotective,
hemorheologic, anti-inflammatory and anti-thrombotic agent that has potential utility in diseases
or conditions characterized by microcirculatory insufficiency (endothelial dysfunction and/or
impaired blood flow).
The Company is recruiting subjects in EPIC, a pivotal phase 3 study of ANX-188 in sickle cell disease. The Company plans to initiate a phase 2 clinical study of ANX-188 in acute limb ischemia, a complication of peripheral arterial disease, in late 2013 or early 2014. More information can be found on the Companys web site at www.adventrx.com.
Forward Looking Statements
ADVENTRX cautions you that statements included in this press release that are not a description of
historical facts are forward-looking statements that are based on ADVENTRXs current expectations
and assumptions. Such forward-looking statements include, but are not limited to, statements
regarding ADVENTRXs development plans for ANX-188 in acute limb ischemia and other complications
of arterial disease and the timing of activities related to those plans. Among the factors that
could cause or contribute to material differences between ADVENTRXs actual results and
expectations indicated by the forward-looking statements are risks and uncertainties that include,
but are not limited to: the potential for delays in the commencement or completion of clinical
studies, including as a result of difficulties in obtaining regulatory agency agreement on clinical
development plans or clinical study design, opening trial sites, enrolling study subjects,
manufacturing clinical trial material, completing manufacturing process development activities, and
being subject to a clinical hold; the risk of suspension or termination of a clinical study,
including due to lack of adequate funding or patient safety concerns; the potential for
institutional review boards or the FDA or other regulatory agencies to require additional
nonclinical or clinical studies prior to initiation of planned phase 2 clinical studies of ANX-188
in any particular indication in which ADVENTRX determines to develop ANX-188, including ALI, which
likely would increase the total time and cost of development in the indication; the risk that
clinical studies of ANX-188 are not successfully executed and/or do not successfully demonstrate
its safety or efficacy; the risk that, even if clinical studies are successful, the FDA determines
they are not sufficient to support a new drug application; the risk that even if clinical studies
of ANX-188 in one indication are successful, clinical studies in another indication may not be
successful; ADVENTRXs reliance on contract research organizations (CROs), contract manufacturing
organizations (CMOs), and other third parties to assist in the conduct of important aspects of
development of ANX-188, including clinical studies, and regulatory activities for ANX-188 and that
such third parties may fail to perform as expected; ADVENTRXs ability to obtain additional funding
on a timely basis or on acceptable terms, or at all; the potential for ADVENTRX to delay, reduce or
discontinue current and/or planned development activities, including clinical studies, partner
ANX-188 at inopportune times or pursue less expensive but higher-risk development paths if it is
unable to raise sufficient additional capital as needed; the risk that acceptable partnering
opportunities for ANX-188 may not be available in particular jurisdictions or indications and,
consequently, ADVENTRX may not be able to pursue development of ANX-188 in certain jurisdictions
and indications; the risk that the FDA does not grant marketing approval of ANX-188, on a timely
basis, or at all; the risk that ADVENTRX is not able to adequately protect its intellectual
property rights relating to the MAST platform and ANX-188 and prevent competitors from duplicating
or developing equivalent versions of its product candidates, including ANX-188; and other risks and
uncertainties more fully described in ADVENTRXs press releases and periodic filings with the
Securities and Exchange Commission. ADVENTRXs public filings with the Securities and Exchange
Commission are available at www.sec.gov.
You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date when made. ADVENTRX does not intend to revise or update any forward-looking statement set forth in this press release to reflect events or circumstances arising after the date hereof, except as may be required by law.
Contact: |
ADVENTRX Pharmaceuticals Ioana C. Hone (ir@adventrx.com) |
858-552-0866 Ext. 303 |
# # #